Subcutaneous injection of the incretin hormone glucagon-like peptide 1 abolishes postprandial glycemia in NIDDM

Diabetes Care

Volumn 17, Issue 9, 1994, Pages 1039-1044

  Gutniak, Mark K ^a   Linde, Birgitta ^a   Holst, Jens J ^b   Efendić, Suad ^a  

^a KAROLINSKA INSTITUTE   (Sweden)

^b UNIVERSITY OF COPENHAGEN   (Denmark)

Author keywords

[No Author keywords available]

Indexed keywords

C PEPTIDE; GLUCAGON LIKE PEPTIDE 1; GLUCOSE; INCRETIN; INSULIN; UNCLASSIFIED DRUG;

ADULT; ARTICLE; CLINICAL ARTICLE; DOSE RESPONSE; DRUG EFFECT; FEMALE; HORMONE RESPONSE; HUMAN; HYPERGLYCEMIA; INTRAMUSCULAR DRUG ADMINISTRATION; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; OBESITY; POSTPRANDIAL STATE;

EID: 0028071448     PISSN: 01495992     EISSN: None     Source Type: Journal    
DOI: 10.2337/diacare.17.9.1039     Document Type: Article

References (29)

1. Kreymann B, Williams G, Ghatei MA, Bloom SR: Glucagon-like peptide-1 7-36: a physiological incretin in man. Lancet 2:1300-1303, 1987
2. Fehmann HC, Göke R, Göke B: Glucagon-like peptide-1(7-37)/(7-36)amide is a new incretin. Mol Cell Endocrinol 85: C39-C44, 1992
3. Nauck MA, Heimesaat MM, Orskov C, Holst JJ, Ebert R, Creutzfeldt W: Preserved incretin activity of glucagon-like peptide 1 (7-36)amide but not of synthetic human gastric inhibitory polypeptide in patients with type 2 diabetes mellitus. J Clin Invest 91:301-307, 1993
4. Gutniak MK, Orskov C, Holst JJ, Ahrén B, Efendic S: Antidiabetogenic effect of glucagon-like peptide-1 (7-36)amide in normal subjects and patients with diabetes mellitus. N Engl J Med 326:1992
5. Nathan DM, Schreiber E, Mojsov S, Habener JF: Insulinotropic action of glucagon-like peptide-1-(7-37) in diabetic and nondiabetic subjects. Diabetes Care 15:270-276, 1992
6. Nauck MA, Kleine N, Orskov C, Holst JJ, Willms B, Creutzfeldt W: Normalization of fasting hyperglycaemia by exogenous glucagon-like peptide 1 (7-36)amide in type 2 (non-insulin-dependent) diabetic patients. Diabetologia 36:741-744, 1993
7. National Diabetes Data Group: Classification and diagnosis of diabetes mellitus and other catgories of glucose intolerance. Diabetes 28:1039-1057, 1979
8. Hugget AS, Nixon DA: Use of glucose oxidase peroxidase and o-dianisidine in determination of blood and urinary glucose. Lancet 2:368-370, 1957
9. Simon M, Cuan J: Haemoglobin A1c isoelectric focusing. Clin Chem 28:9-12, 1982
10. Gennaro WE, Van Norman ID: Quantitation of free-, total-, and antibody-bound insulin in insulin-treated diabetics. Clin Chem 21:873-879, 1975
11. Holst JJ, Bersani M: Assays for the peptide products of somatostain gene expression. In Methods in Neurosciences: Peptides. Vol 5. Conn PM, Ed. New York, Academic, 1991, p. 3-22.
12. Orskov C, Jeppesen J, Madsbad S, Holst JJ: Proglucagon products in plasma of non-insulin-dependent diabetics and nondiabetic controls in the fasting state and after oral glucose and intravenous arginine. J Clin Invest 87:415-423, 1991
13. Holst JJ: Evidence that enteroglucagon (II) is identical with the C-terminal sequence (residue 33-69) of glicentin. Biochem J 207:381-388, 1982
14. Ørskov C: Glucagon-like peptide 1, a new hormone of the enteroinsular axis. Diabetologia 35:701-711, 1992
15. Ørskov C, Rabenhøj L, Wettergren A, Kofod H, Holst JJ: Tissue and plasma concentrations of amidated and glycine-extended glucagon-like peptide 1 in humans. Diabetes 43:535-539
16. Lebovitz HE, Feinglos MN: Sulfonylurea drugs: mechanism of antidiabetic action and therapeutic usefulness. Diabetes Care 1:189-198, 1978
17. Robertson DA, Hale PJ, Nattrass M: Macrovascular disease and hyperinsulinaemia. In Baillière's Clinical Endocrinology and Metabolism. Nattrass M, Hale PJ, Eds. London, Bailliere Tindall, 1988, p. 407-424
18. Gutniak MK, Karlander SG, Efendic S: Glyburide decreases insulin requirement, increases β-cell response to mixed meal, and does not affect insulin sensitivity: effects of short- and long-term combined treatment in secondary failure to sulfonylurea. Diabetes Care 100:545-554, 1987
19. Scheen AJ, Lefèbvre PJ: Insulin versus insulin plus sulfonylureas in type 2 diabetic patients with secondary failure to sulfonylureas. Diabetes Res Clin Pract 6:533-S43, 1989
20. Gutniak MK, Linde B, Efendic S: Subcutaneous injection of glucagon-like insulinotropic peptide reduces postprandial glycemia in non-insulin-dependent diabetes. Digestion 54:389-390, 1993
21. Wettergren A, Schjoldager B, Mortensen PE, Myhre J, Christiansen J, Holst JJ: Truncated GLP-1 (proglucagon 78-107-amide) inhibits gastric and pancreatic functions in man. Dig Dis Sci 38:665-673, 1993
22. Ferrannini E, Cobelli C: The kinetics of insulin in man. Diabetes Metab Rev 3:335-363, 1987
23. Ørskov C, Wettergren A, Holst JJ: Biological effects and metabolic rates of glucagonlike peptide-1 7-36 amide and glucagonlike peptide-1 7-37 in healthy subjects are indistinguishable. Diabetes 42:658-661, 1993
24. Brange J, Owens DR, Kang S, Volund A: Monomeric insulins and their experimental and clinical implications. Diabetes Care 13:923-954, 1990
25. Muhlhauser IK, Berger M: Pharmacokinetics and bioavailability of injected glucagon: differences between intramuscular, subcutaneous, and intravenous administration. Diabetes Care 8:39-42, 1985
26. Kreymann B Bloom SR: Glucagon and gut hormones in diabetes mellitus. In Textbook of Diabetes. Pickup J, Williams G, Eds. Oxford, Blackwell Scientific, 1991, p. 313-324
27. Simmons KL, Williams G: Attempts to accelerate glucagon absorption: effects of adding a vasodilator and of injection using a "sprinkler" needle. Eur J Clin Invest 22:434-437, 1989
28. Williams G, Pickup JC, Collins AGC, Keen H: Prostaglandin E1 accelerates sub-cutaneous insulin absorption in insulin-dependent diabetic patients. Diabetic Med 1:109-112, 1984
29. Binder C: Absorption of injected insulin. Acta Pharmacol Toxicol 27 (Suppl. 2):1-87, 1969